The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Quantitative monitoring of ketamine’s impact on synaptic density using 11C-UCB-J PET imaging in the corticosterone mouse model of anxiety/depression
Abstract
Ketamine was shown to promote synaptogenesis, which is thought to account for its antidepressant effects through the restoration of lost synaptic connections observed in depression. PET imaging using 11 C-UCB-J, a radiotracer targeting the synaptic vesicle protein 2 A (SV2A), was investigated as a translational method to monitor ketamine-induced changes in synaptic density in the corticosterone (CORT) mouse model of anxiety/depression. Male CORT and healthy control mice received either a single dose of ketamine (10 mg/kg, i.p) or a repeated-dose regimen (3 doses in total). Brain PET imaging was performed either 24 h after the single dose or 1 or 3 weeks after the repeated-dose regimen to estimate the binding of 11 C-UCB-J in each condition. A global decrease in the binding of 11 C-UCB-J was observed in CORT mice compared to control mice, indicating synaptic loss. In CORT mice, behavioral experiments showed antidepressant effects of ketamine 24 h after a single dose, although no significant changes in 11 C-UCB-J binding could be observed at this time point. Three weeks after the repeated dose regimen, ketamine restored the binding of 11 C-UCB-J in CORT mice to the level of age-matched untreated healthy controls. The reversal of synaptic loss was associated with delayed antidepressant effects in behavioural tests. Ex vivo expression of SV2A protein measured under different conditions was strongly correlated with the in vivo binding of 11 C-UCB-J and the postsynaptic marker PSD95. These results support the molecular interpretation of SV2A PET imaging to monitor drug-induced synaptogenesis as a determinant of antidepressant efficacy from a translational perspective.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a translational biomarker, SV2A PET is well-positioned to monitor antidepressant-induced synaptic restoration [215,216,217,218].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [217]
In the citing paper
“Proof-of-concept data demonstrate partial recovery after fluoxetine in a depression model, and early work suggests ketamine may normalize low-baseline SV2A signal, linking circuit plasticity to presynaptic stabilization [167,217,218].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [217]
In the citing paper
“Proof-of-concept data demonstrate partial recovery after fluoxetine in a depression model, and early work suggests ketamine may normalize low-baseline SV2A signal, linking circuit plasticity to presynaptic stabilization [167,217,218].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [217]
Citations
Cites
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Moy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., Piven, J., & Crawley, J. N. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-1848.2004.00076.x · Cited by 1,522
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
David, D. J., Samuels, B. A., Rainer, Q., Wang, J.-W., Marsteller, D., Mendez, I., Drew, M., Craig, D. A., Guiard, B. P., Guilloux, J.-P., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.04.017 · Cited by 1,267
Self-citationMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Liston, C., Miller, M. M., Goldwater, D. S., Radley, J. J., Rocher, A. B., Hof, P. R., Morrison, J. H., & McEwen, B. S. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1184-06.2006 · Cited by 968
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Duric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304
Discovering imaging endophenotypes for major depression
Hasler, G., & Northoff, G. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.23 · Cited by 274
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb
Ma, S., Chen, M., Jiang, Y., Xiang, X., Wang, S., Wu, Z., Li, S., Cui, Y., Wang, J., Zhu, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06624-1 · Cited by 204
Rodent tests of depression and anxiety: Construct validity and translational relevance
Gencturk, S., & Ünal, G. (2024) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-024-01171-2 · Cited by 175
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Synaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Modeling treatment-resistant depression
Samuels, B. A., Leonardo, E. D., Gadient, R. A., Williams, A., Zhou, J., David, D. J. P., Gardier, A. M., Wong, E. H. F., & Hen, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.017 · Cited by 99
Self-citationPage, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
Hodes, G. E., Hill‐Smith, T. E., & Lucki, I. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.07.084 · Cited by 78
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
Mendez‐David, I., Guilloux, J., Papp, M., Tritschler, L., Mocaër, E., Gardier, A. M., Bretin, S., & David, D. J. P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00462 · Cited by 66
Self-citationPostsynaptic density protein 95 (PSD-95) is transported by KIF5 to dendritic regions
Yoo, K., Lee, K., Oh, J.-Y., Lee, H., Park, H., Park, Y. S., & Kim, H. K. (2019) · Molecular Brain · doi:10.1186/s13041-019-0520-x · Cited by 62
von Mücke-Heim, I.-A., Urbina-Treviño, L., Bordes, J., Ries, C., Schmidt, M. V., & Deussing, J. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01762-w · Cited by 61
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740996 · Cited by 55
Validation and noninvasive kinetic modeling of [ 11 C]UCB-J PET imaging in mice
Bertoglio, D., Verhaeghe, J., Miranda, A., Kertesz, I., Cybulska, K., Korat, Š., Wyffels, L., Stroobants, S., Mrzljak, L., Dominguez, C., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19864081 · Cited by 54
Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02285-8 · Cited by 53
Lisek, M., Ferenc, B., Studzian, M., Pułaski, Ł., Guo, F., Żylińska, L., & Boczek, T. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00181 · Cited by 48
Agasse, F., Mendez-David, I., Christaller, W., Carpentier, R., Braz, B. Y., David, D. J., Saudou, F., & Humbert, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107865 · Cited by 43
Self-citationRayan, N. A., Kumar, V., Aow, J., Rastegar, N., Lim, M. G. L., O’Toole, N., Aliwarga, E., Arcego, D. M., Yeo, G. H. T., Wong, J. Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01725-1 · Cited by 42
The Rise of Synaptic Density PET Imaging
Becker, G., Dammicco, S., Bahri, M. A., & Salmon, É. (2020) · Molecules · doi:10.3390/molecules25102303 · Cited by 37
Wang, H., Wang, X., Wang, H., Shao, S.-J., & Zhu, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011245 · Cited by 37
Tracing synaptic loss in Alzheimer's brain with SV2A PET‐tracer UCB‐J
Kumar, A., Scarpa, M., & Nordberg, A. K. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13720 · Cited by 37
Synaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
Bavarsad, M. S., Spina, S., Oehler, A., Allen, I. E., Suemoto, C. K., Leite, R. E. P., Seeley, W. S., Green, A., Jagust, W., Rabinovici, G. D., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02816-9 · Cited by 31
Prolonged anesthesia alters brain synaptic architecture
Wenzel, M., Leunig, A., Han, S., Peterka, D. S., & Yuste, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023676118 · Cited by 23
Sephton, S. M., Miklovicz, T., Russell, J. J., Doke, A. K., Li, L., Boros, I., & Aigbirhio, F. I. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3828 · Cited by 23
Fraga, D. B., Camargo, A., Olescowicz, G., Padilha, D. A., Mina, F., Budni, J., Brocardo, P. S., & Rodrigues, A. L. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00743-2 · Cited by 21
Zhang, Y., Wei, C., Wang, P., Zheng, L.-C., Cheng, Y., Ren, Z., Jin, Y., Yao, Y., & Liu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-76226-y · Cited by 20
Yoshioka, T., Yamada, D., Hagiwara, A., Kajino, K., Iio, K., Saitoh, T., Nagase, H., & Saitoh, A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02814-z · Cited by 16
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Wang, C., Lan, X., Liu, W., Zhan, Y., Zheng, W., Chen, X., Liu, G., Mai, S., Lu, H., McIntyre, R. S., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03027-2 · Cited by 10
Chronic corticosterone deteriorates latrine and nesting behaviours in mice
Nomoto, K., & Kansaku, K. (2023) · Royal Society Open Science · doi:10.1098/rsos.220718 · Cited by 8
Huang, B., Li, X., Zheng, Y., Mai, Y., & Zhang, Z. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13736 · Cited by 8
Corvo, C., Mendez-David, I., Goutal, S., Saba, W., Bottlaender, M., Caillé, F., Hen, R., Colle, R., Corruble, E., Tournier, N., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00621 · Cited by 7
Self-citationKetamine for resistant depression: a scoping review.
Eduardo, T.-Q., Acero-González, D. Á., Mateo, L., Melanie, L.-Z., Valentina, P.-F., David, C., Collazos, E., Natalia, R.-S., Andrés, V.-C., Angel, R.-O., et al. (2022) · PubMed Central · Cited by 7
The pharmacological management of treatment-resistant depression: what does the future hold?
Serretti, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2287011 · Cited by 4
Cited by
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
Metadata
- Authors
- Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., Leroy, C., David, D. J., & Tournier, N.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Corresponding author
- Tournier, Nicolas
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2025-11-18
- Volume
- 31
- Issue
- 4
- Pages
- 1946-1957
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W4416332480
- Cited by
- 1
- References
- 54
- Citations by year
- 2026: 1
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-22-CE17-0015, ANR-11-INBS-0006)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine, synaptic density, synaptogenesis, [11C]UCB-J, SV2A, depression, anxiety, antidepressant efficacy, synaptic loss, PSD-95, positron emission tomography
- MeSH terms
- Animals, Antidepressive Agents, Anxiety, Brain, Carbon Radioisotopes, Corticosterone, Depression, Disease Models, Animal, Ketamine, Male, Mice, Inbred C57BL, Pyridines, Pyrrolidinones, Synapses, Positron-Emission Tomography, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.